Skip to Content

Any cancer program can create a glossy annual report touting their program’s attributes. However, the American Society of Clinical Oncology, American College of Surgeons and the National Cancer Institute recognize that the challenge to cancer care quality is ensuring that patients are receiving the care known to be effective for their disease. The table below assesses adherence to and consideration of standard of care therapies for major cancers.

Cancer outcomes

How we compare* CHOMP CA US

Higher is better

Hormone therapy for breast cancer

For a specific type of breast cancer, hormone therapy after surgery, such as use of the drug Tamoxifen, clearly decreases the risk of recurrence.

Breast conservation surgery rate with stage O, I, or II breast cancer.

Better 80% 61% 63%

Radiation therapy for breast cancer

Radiation therapy after partial mastectomy or lumpectomy dramatically decreases the risk of recurrence.

Radiation therapy is considered or administered following any mastectomy within one year of diagnosis of breast cancer of women with ≥4 positive regional lymph nodes.

Better 100% 83.5% 87.5%

Lymph node removal to determine stage of colon cancer

Removal and evaluation of at least 12 lymph nodes next to a patient’s colon cancer enables the doctor to adequately determine whether the cancer has spread to the lymph nodes.  If so, additional treatment will decrease chances of recurrence. 

Systemic chemotherapy is administered within 4 months before surgery or 6 months after surgery for Non-Small Cell Lung Cancer where cancer has spread to the pN1 and pN2 lymph nodes.

Better 100% 86.4% 89.5%

*As compared to national benchmark